[1-(2-phenoxyethyl)-3-indolyl]-(1-pyrrolidinyl)methanethione is a chemical compound that is not widely known or researched. It is likely a synthetic compound that has not yet been extensively studied.
Here's why it is difficult to determine its importance for research:
* **Lack of Published Research:** There's no readily available information about this specific compound in scientific databases or literature. This suggests it may not have been studied in depth, or its research is limited to specific labs and not yet published.
* **Novel Compound:** It could be a novel compound that has not been fully characterized or tested for its properties. Researchers may be investigating its potential applications in different fields, like medicine or materials science.
* **Incomplete Name:** The name provided might not be the complete or standardized chemical name. This could lead to difficulty finding information about the compound.
**To better understand its potential importance, we need more information:**
* **Who is researching it?** Knowing the research group or institution involved might help understand the research focus and potential applications.
* **What are its properties?** Information on its chemical structure, physical properties, and biological activity is crucial to assess its significance.
* **What is its intended use?** Knowing the research objectives behind studying this compound will provide context for its importance.
**In summary:** [1-(2-phenoxyethyl)-3-indolyl]-(1-pyrrolidinyl)methanethione is a chemical compound that requires further investigation to understand its potential relevance in research.
ID Source | ID |
---|---|
PubMed CID | 1324805 |
CHEMBL ID | 1407203 |
CHEBI ID | 122177 |
Synonym |
---|
HMS1483B13 |
[1-(2-phenoxyethyl)indol-3-yl]-pyrrolidin-1-ylmethanethione |
VU0040975-1 |
IDI1_021465 |
smr000196711 |
MLS000575677 , |
1-(2-phenoxyethyl)-3-(1-pyrrolidinylcarbonothioyl)-1h-indole |
OPREA1_293845 |
CHEMDIV3_003555 |
CHEBI:122177 |
BRD-K39317701-001-01-8 |
MLS-0109562.0001 , |
AKOS001674219 |
HMS2324D18 |
bdbm46206 |
[1-(2-phenoxyethyl)indol-3-yl]-pyrrolidino-methanethione |
cid_1324805 |
[1-(2-phenoxyethyl)indol-3-yl]-pyrrolidin-1-yl-methanethione |
[1-(2-phenoxyethyl)-3-indolyl]-(1-pyrrolidinyl)methanethione |
[1-(2-phenoxyethyl)-1h-indol-3-yl](pyrrolidin-1-yl)methanethione |
STL426475 |
CHEMBL1407203 |
SR-01000501136-1 |
sr-01000501136 |
Q27210825 |
1-(2-phenoxyethyl)-3-(pyrrolidine-1-carbothioyl)-1h-indole |
Class | Description |
---|---|
indoles | Any compound containing an indole skeleton. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 7.9433 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
Chain A, Cruzipain | Trypanosoma cruzi | Potency | 31.6228 | 0.0020 | 14.6779 | 39.8107 | AID1476 |
glp-1 receptor, partial | Homo sapiens (human) | Potency | 12.5893 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
phosphopantetheinyl transferase | Bacillus subtilis | Potency | 35.4813 | 0.1413 | 37.9142 | 100.0000 | AID1490 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 20.5962 | 0.0041 | 10.8903 | 31.5287 | AID504466 |
TDP1 protein | Homo sapiens (human) | Potency | 18.8677 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
Smad3 | Homo sapiens (human) | Potency | 14.1254 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
PINK1 | Homo sapiens (human) | Potency | 50.1187 | 2.8184 | 18.8959 | 44.6684 | AID624263 |
67.9K protein | Vaccinia virus | Potency | 22.8741 | 0.0001 | 8.4406 | 100.0000 | AID720579; AID720580 |
Parkin | Homo sapiens (human) | Potency | 50.1187 | 0.8199 | 14.8306 | 44.6684 | AID624263 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 35.4813 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 35.4813 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
huntingtin isoform 2 | Homo sapiens (human) | Potency | 22.3872 | 0.0006 | 18.4198 | 1,122.0200 | AID1688 |
importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 125.8920 | 5.8048 | 36.1306 | 65.1308 | AID540263 |
serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 28.1838 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
snurportin-1 | Homo sapiens (human) | Potency | 125.8920 | 5.8048 | 36.1306 | 65.1308 | AID540263 |
histone-lysine N-methyltransferase 2A isoform 2 precursor | Homo sapiens (human) | Potency | 39.8107 | 0.0103 | 23.8567 | 63.0957 | AID2662 |
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 89.1251 | 0.4256 | 12.0591 | 28.1838 | AID504891 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 21.5717 | 0.0079 | 8.2332 | 1,122.0200 | AID2551; AID2762; AID2763 |
Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) | Potency | 25.1189 | 0.3162 | 12.7657 | 31.6228 | AID881 |
Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 25.1189 | 0.0063 | 8.2350 | 39.8107 | AID881 |
Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 37.6188 | 1.9953 | 25.5327 | 50.1187 | AID624287; AID624288 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
tyrosine-protein phosphatase non-receptor type 11 isoform 1 | Homo sapiens (human) | IC50 (µMol) | 5.4700 | 0.1600 | 3.3759 | 9.8800 | AID602367 |
dual specificity protein phosphatase 3 | Homo sapiens (human) | IC50 (µMol) | 22.7534 | 0.4000 | 9.3610 | 90.0000 | AID1654; AID1878; AID1957; AID1958; AID602374 |
tyrosine-protein phosphatase non-receptor type 5 isoform a | Homo sapiens (human) | IC50 (µMol) | 33.2000 | 4.1700 | 12.5457 | 19.0000 | AID602372; AID624207 |
tyrosine-protein phosphatase non-receptor type 22 isoform 1 | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.4800 | 2.6449 | 8.3270 | AID624241 |
dual specificity protein phosphatase 6 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 128.5000 | 0.8320 | 24.1190 | 48.2000 | AID1055; AID425 |
tyrosine-protein phosphatase non-receptor type 7 isoform 2 | Homo sapiens (human) | IC50 (µMol) | 0.5680 | 0.1000 | 12.7265 | 63.0000 | AID1077; AID2068 |
Renin | Homo sapiens (human) | IC50 (µMol) | 3.9700 | 0.0000 | 0.7796 | 8.2000 | AID1654 |
cAMP-specific 3',5'-cyclic phosphodiesterase 4D | Rattus norvegicus (Norway rat) | IC50 (µMol) | 99.0000 | 0.0003 | 2.7232 | 10.0000 | AID1957 |
cAMP-specific 3',5'-cyclic phosphodiesterase 4C | Rattus norvegicus (Norway rat) | IC50 (µMol) | 99.0000 | 0.0003 | 2.7232 | 10.0000 | AID1957 |
cAMP-specific 3',5'-cyclic phosphodiesterase 4B | Rattus norvegicus (Norway rat) | IC50 (µMol) | 99.0000 | 0.0003 | 2.6638 | 10.0000 | AID1957 |
Amine oxidase [flavin-containing] B | Rattus norvegicus (Norway rat) | IC50 (µMol) | 0.7270 | 0.0004 | 0.7649 | 12.5000 | AID1958 |
Amine oxidase [flavin-containing] A | Rattus norvegicus (Norway rat) | IC50 (µMol) | 0.7270 | 0.0007 | 1.9798 | 12.5000 | AID1958 |
cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Rattus norvegicus (Norway rat) | IC50 (µMol) | 99.0000 | 0.0003 | 2.7232 | 10.0000 | AID1957 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (14.29) | 29.6817 |
2010's | 5 (71.43) | 24.3611 |
2020's | 1 (14.29) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.20) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |